Literature DB >> 8432501

Personality disorders diagnosed at intake at a public psychiatric facility.

H Fabrega1, R Ulrich, P Pilkonis, J Mezzich.   

Abstract

OBJECTIVE: The purpose of the study was to determine the prevalence of personality disorders among a large population of persons seeking treatment in a public psychiatric facility and to examine the role of personality disorders in the clinical conditions of persons frequenting such facilities.
METHODS: Clinical and demographic data were retrospectively examined for 18,179 adults who visited a walk-in clinic of a public psychiatric facility between 1983 and 1989. Patients who received a diagnosis of personality disorder were compared with those who did not.
RESULTS: A total of 2,344 patients (12.9 percent) were diagnosed as having a personality disorder, a lower prevalence rate than generally found in treatment populations. The most frequent diagnoses were atypical, antisocial, and borderline personality disorders. Compared with other subjects, those with a personality disorder were significantly more likely to be men, to be 35 years old or younger, to have a higher level of social impairment, and to have more symptoms and more severe symptoms.
CONCLUSIONS: The relatively low prevalence rate was attributed in part to underdiagnosis, largely due to the need for making rapid assessments in a public intake setting. The authors conclude that clinicians in such facilities may be likely to diagnose personality disorders when patients with certain axis I disorders such as substance use, affective, and adjustment disorders present with an overall greater level of symptomatology and social impairment.

Entities:  

Mesh:

Year:  1993        PMID: 8432501     DOI: 10.1176/ps.44.2.159

Source DB:  PubMed          Journal:  Hosp Community Psychiatry        ISSN: 0022-1597


  1 in total

1.  Affective disorders among patients with borderline personality disorder.

Authors:  Hege Nordem Sjåstad; Rolf W Gråwe; Jens Egeland
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.